Khdair Sawsan I, Waleed Mohammed, Hammad Alaa M, Al-Khareisha Lubna, Jaber Tariq, Ayash Majd, Hall Frank Scott
Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman 11733, Jordan.
Department of Pharmacy, Al-Bashir Hospital, Ashrafeya, P.O. Box 10005, Amman 11151, Jordan.
Life (Basel). 2025 May 26;15(6):859. doi: 10.3390/life15060859.
Central nervous system autoimmune disorders, like multiple sclerosis (MS), are chronic conditions where cytokines contribute significantly to the regulation of inflammation. The diagnosis, progression, and treatment effectiveness of MS are assessed through laboratory tests and clinical evaluation, as well as imaging.
This study included 40 healthy individuals as a control group and 75 MS patients, divided into two groups: 45 MS patients receiving fingolimod treatment (MSW) and 30 patients taking other medications (MSOs). Blood samples (3 mL) were collected from all participants, and the mRNA relative expression of cytokine genes (, , , and ) was measured. Additionally, MRI images of MS patients undergoing fingolimod or other treatments were analyzed.
The MSO patient group displayed higher mRNA expressions of , , , and compared to the control group. Furthermore, , , and expressions were elevated in the MSO group compared to the MSW group. MRI scans showed significant improvement in MS patients taking fingolimod compared to those receiving other medications.
Fingolimod demonstrated greater effectiveness in improving MS patients' conditions, possibly due to its impact on cytokine expression.
中枢神经系统自身免疫性疾病,如多发性硬化症(MS),是一种慢性疾病,细胞因子在其中对炎症调节起着重要作用。MS的诊断、病情进展及治疗效果通过实验室检查、临床评估以及影像学检查来评估。
本研究纳入40名健康个体作为对照组,75名MS患者分为两组:45名接受芬戈莫德治疗的MS患者(MSW组)和30名服用其他药物的患者(MSO组)。采集所有参与者的血样(3毫升),检测细胞因子基因(、、、)的mRNA相对表达量。此外,对接受芬戈莫德或其他治疗的MS患者的MRI图像进行分析。
与对照组相比,MSO患者组的、、、的mRNA表达更高。此外,与MSW组相比,MSO组的、和表达升高。MRI扫描显示,与接受其他药物治疗的患者相比,服用芬戈莫德的MS患者有显著改善。
芬戈莫德在改善MS患者病情方面显示出更大的疗效,可能是由于其对细胞因子表达的影响。